文章摘要
王学博,符攀峰,任红娟,等.紫杉醇、顺铂方案联合腹腔热灌注化疗对晚期卵巢癌病人免疫功能及生存质量的影响[J].安徽医药,2022,26(4):791-795.
紫杉醇、顺铂方案联合腹腔热灌注化疗对晚期卵巢癌病人免疫功能及生存质量的影响
Effect of paclitaxel, cisplatin regimen combined with intraperitoneal hyperthermic perfusion chemotherapy on immune function and quality of life in patients with advanced ovarian cancer
  
DOI:10.3969/j.issn.1009-6469.2022.04.034
中文关键词: 卵巢肿瘤  红豆杉  顺铂  化学疗法,肿瘤,局部灌注  腹腔灌洗  紫杉醇  热灌注化疗  免疫功能  生存质量
英文关键词: Ovarian neoplasms  Taxus  Cisplatin  Chemotherapy, cancer, local perfusion  Peritoneal lavage  Paclitaxel  Hyperthermic perfusion chemotherapy  Immune function  Quality of life
基金项目:
作者单位E-mail
王学博 南阳市中心医院,妇产科河南,南阳 473000  
符攀峰 南阳市口腔医院病理科河南南阳 473000 fupanfeng1976@163.com 
任红娟 南阳市中心医院,妇产科河南,南阳 473000  
李松 南阳市中心医院,妇产科河南,南阳 473000  
陈芳 南阳市中心医院,妇产科儿科河南,南阳 473000  
渣盈冰 南阳市中心医院,妇产科河南,南阳 473000  
杨冉 南阳市中心医院,妇产科河南,南阳 473000  
摘要点击次数: 1133
全文下载次数: 403
中文摘要:
      目的探讨紫杉醇、顺铂方案( TP方案)联合腹腔热灌注化疗对晚期卵巢癌病人免疫功能及生存质量的影响。方法选取 2016年 1月至 2019年 1月南阳市中心医院 72例晚期卵巢癌病人,随机数字表法分为观察组和对照组,各 36例。对照组给予单纯紫杉醇、顺铂方案静脉化疗,观察组在静脉化疗的基础上,在末次化疗后第 8天进行腹腔热灌注化疗,顺铂用量为 60 mg,每次热灌注化疗时间为 90 min。比较两组病人的 T淋巴细胞亚群检测结果;比较两组病人的生存质量改善情况、不良反应发生情况以及 1年的生存情况。结果两组病人治疗前分化簇 3阳性( CD3+)、分化簇 4阳性( CD4+)、分化簇 8阳性( CD8+)及 CD4+/CD8+比例差异无统计学意义( P>0.05),治疗后 6个月两组 CD3+,CD4+,CD4+/CD8+高于治疗前( P<0.05),而 CD8+低于治疗前( P<0.05)治疗后 6个月观察组 CD3+CD4+%,CD4+/CD8+高于对照组( P<0.05)CD8+低于对照组( P<0.05)。治疗前两组 Ka mofsky(KPS)生,活状态量表评分差异无统计,学意义( P>0.05),治疗后观察组 KPS评分,较治疗前增高(P<0.05),且显著高于对照组( P<0.05)。观察组化疗后生存质量提高的比例为 63.89%,高于对照组的 38.89%(P<0.05);观察组胃肠道反应发生率为
英文摘要:
      Objective To investigate the effect of paclitaxel, cisplatin (TP) regimen combined with intraperitoneal hyperthermic per fusion chemotherapy on immune function and quality of life in patients with advanced ovarian cancer.Methods A total of 72 patientswith advanced ovarian cancer in Nanyang Central Hospital from January 2016 to January 2019 were selected and randomly divided intoan observation group and a control group, with 36 cases in each group. The control group was given intravenous chemotherapy with TPalone, and the observation group was given intraperitoneal hyperthermic perfusion chemotherapy on the basis of intravenous chemother apy on the 8th day after the last chemotherapy. The dosage of cisplatin was 60 mg and the time of each hyperthermic perfusion chemo therapy was 90min. The detection results of T lymphocyte subsets of the two groups of patients were compared, the improvement of thequality of life, the occurrence of adverse reactions and the 1-year survival of the two groups of patients were compared.Results Before treatment, there was no significant difference in cluster 3 positive (CD3+), cluster 4 positive (CD4+), cluster 8 positive (CD8+) and CD4+/CD8+ ratio between the two groups (P>0.05). Six months after treatment, CD3+, CD4+, CD4+/CD8+ ratio in the two groups were higher than before treatment (P<0.05), while CD8+ was lower than before treatment (P<0.05). Meanwhile, CD3+, CD4+, CD4+/CD8+ ratio in the observation group were higher than those in the control group (P<0.05), and CD8+ was lower than that in the control group (P<0.05). Before treatment, there was no significant difference in Kamofsky (KPS) living state scale score between the two groups (P>0.05), but af ter treatment, the KPS score in the observation group was higher than that before treatment (P<0.05), and was significantly higher than that in the control group (P<0.05). The improvement rate of quality of life in the observation group after chemotherapy was 63.89%,
查看全文   查看/发表评论  下载PDF阅读器
关闭

分享按钮